"Daraprim is still underpriced, relative to its peers."
daraprim is still underpriced relative to its peers
shkreli the ceo of turing pharmaceuticals said daraprim is still underpriced relative to its peers
martin shkreli claim that daraprim is relative to its peers
by his own estimates daraprim is cheaper than cancer and rare disease drugs which he considers daraprim s peers
daraprim meanwhile is generic drug
